“…The procedural success rate of only 73% compared with reported rates of 90% to 97% in more recent studies (2,(5)(6)(7)9) is related to learning phase factors as well as a very conservative definition used in this study requiring MACCE-free in-hospital survival, without which the technical success rate was 83%. Similarly, the 30-day mortality rate of 15.2% in this study appears to be high in the light of more recent TAVI studies, which report 30-day mortality rates of 6% to 10% (5)(6)(7)9). In addition to the learning curve issues and various improvements described, that might be related to a tendency to treat patients with less comorbidity today than in the early phase of TAVI, as is reflected in this paper.…”